Clinical Trial Update: AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 study of AIN457 (secukinumab) for moderate-to-severe plaque psoriasis completed, with results posted in 2015. Sponsor: Novartis Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• AIN457

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Plaque-type Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2015-03-27